Genetically  	Genetically  	 RB	O
modified  	modified  	 VBN	O
cellular  	cellular  	 JJ	B-NP
vaccines  	vaccines  	 NNS	I-NP
against  	against  	 IN	O
human  	human  	 JJ	O
papillomavirus  	papillomavirus  	 JJ	B-NP
type  	type  	 NN	I-NP
16  	16  	 CD	O
( 	( 	 -LRB-	B-NP
HPV16 	HPV16 	 NNP	I-NP
) 	) 	 -RRB-	I-NP
-associated  	-associated  	 JJ	I-NP
tumors 	tumors 	 NNS	I-NP
:  	:  	 :	O
adjuvant  	adjuvant  	 JJ	B-NP
treatment  	treatment  	 NN	I-NP
of  	of  	 IN	O
minimal  	minimal  	 JJ	O
residual  	residual  	 JJ	B-NP
disease  	disease  	 NN	I-NP
after  	after  	 IN	O
surgery 	surgery 	 NN	B-NP
/ 	/ 	 CD	I-NP
chemotherapy  	chemotherapy  	 CD	I-NP
Local  	Local  	 JJ	I-NP
recurrences  	recurrences  	 NN	I-NP
at  	at  	 IN	O
the  	the  	 DT	O
site  	site  	 NN	O
of  	of  	 IN	O
tumor  	tumor  	 NN	B-NP
resection  	resection  	 NNS	I-NP
or  	or  	 CC	O
after  	after  	 IN	O
chemotherapy 	chemotherapy 	 NN	O
,  	,  	 ,	O
as  	as  	 RB	O
well  	well  	 RB	O
as  	as  	 IN	O
distant  	distant  	 JJ	O
micrometastases  	micrometastases  	 NNS	B-NP
represent  	represent  	 VBP	O
major  	major  	 JJ	O
problems  	problems  	 NNS	O
in  	in  	 IN	O
oncology 	oncology 	 NN	B-NP
.  	.  	 .	O
Therapeutic  	Therapeutic  	 JJ	B-NP
strategies  	strategies  	 NNS	I-NP
based  	based  	 VBN	O
on  	on  	 IN	O
insertion  	insertion  	 NN	O
of  	of  	 IN	O
immunostimulatory  	immunostimulatory  	 JJ	B-NP
genes  	genes  	 NNS	I-NP
into  	into  	 IN	O
the  	the  	 DT	O
genome  	genome  	 NN	B-NP
of  	of  	 IN	I-NP
tumor  	tumor  	 NN	I-NP
cells  	cells  	 NNS	I-NP
followed  	followed  	 VBN	O
by  	by  	 IN	O
vaccination  	vaccination  	 NN	O
with  	with  	 IN	O
the  	the  	 DT	O
resulting  	resulting  	 VBG	O
genetically  	genetically  	 RB	O
modified  	modified  	 VBN	O
and  	and  	 CC	O
irradiated  	irradiated  	 JJ	O
cellular  	cellular  	 JJ	B-NP
vaccines  	vaccines  	 NNS	I-NP
represent  	represent  	 VBP	O
a  	a  	 DT	O
new  	new  	 JJ	O
potential  	potential  	 JJ	B-NP
prospect  	prospect  	 NN	I-NP
for  	for  	 IN	O
the  	the  	 DT	O
treatment  	treatment  	 NN	O
of  	of  	 IN	O
cancer  	cancer  	 NN	B-NP
patients 	patients 	 NNS	I-NP
.  	.  	 .	O
These  	These  	 DT	O
strategies  	strategies  	 NNS	O
are  	are  	 VBP	O
based  	based  	 VBN	O
on  	on  	 IN	O
the  	the  	 DT	O
presumption  	presumption  	 NN	O
that  	that  	 IN	O
many 	many 	 JJ	O
,  	,  	 ,	O
if  	if  	 IN	O
not  	not  	 RB	O
all  	all  	 DT	O
tumors 	tumors 	 NNS	O
,  	,  	 ,	O
possess  	possess  	 JJ	O
cell  	cell  	 NN	O
surface  	surface  	 NN	O
antigens  	antigens  	 VBZ	O
capable  	capable  	 JJ	O
of  	of  	 IN	O
being  	being  	 VBG	O
recognized  	recognized  	 VBN	O
by  	by  	 IN	O
defence  	defence  	 JJ	B-NP
effectors  	effectors  	 NN	I-NP
of  	of  	 IN	O
the  	the  	 DT	O
immune  	immune  	 JJ	O
system 	system 	 NN	O
,  	,  	 ,	O
as  	as  	 RB	O
well  	well  	 RB	O
as  	as  	 RB	O
on  	on  	 IN	O
the  	the  	 DT	O
presumption  	presumption  	 NN	O
that  	that  	 IN	O
local  	local  	 JJ	O
treatment  	treatment  	 NN	O
of  	of  	 IN	O
primary  	primary  	 JJ	B-NP
tumors  	tumors  	 NNS	I-NP
can 	can 	 MD	O
,  	,  	 ,	O
due  	due  	 JJ	O
to  	to  	 TO	O
its  	its  	 PRP$	O
immunizing  	immunizing  	 JJ	O
potential 	potential 	 NN	O
,  	,  	 ,	O
result  	result  	 NN	O
also  	also  	 RB	O
in  	in  	 IN	O
the  	the  	 DT	O
inhibition  	inhibition  	 NN	O
of  	of  	 IN	O
distant  	distant  	 JJ	O
metastases 	metastases 	 NN	B-NP
.  	.  	 .	O
Genetically  	Genetically  	 RB	O
modified  	modified  	 VBN	O
cellular  	cellular  	 JJ	B-NP
vaccines  	vaccines  	 NNS	I-NP
were  	were  	 VBD	O
found  	found  	 VBN	O
to  	to  	 TO	O
be  	be  	 VB	O
efficient  	efficient  	 JJ	O
against  	against  	 IN	O
cancer  	cancer  	 NN	O
both  	both  	 CC	O
in  	in  	 IN	O
experimental  	experimental  	 JJ	B-NP
models  	models  	 NNS	I-NP
and  	and  	 CC	O
in  	in  	 IN	O
tumor-bearing  	tumor-bearing  	 JJ	B-NP
patients 	patients 	 NNS	I-NP
.  	.  	 .	O
It  	It  	 PRP	O
was  	was  	 VBD	O
also  	also  	 RB	O
shown  	shown  	 VBN	O
in  	in  	 IN	O
various  	various  	 JJ	O
systems  	systems  	 NNS	O
that  	that  	 IN	O
the  	the  	 DT	O
efficacy  	efficacy  	 NN	O
of  	of  	 IN	O
conventional  	conventional  	 JJ	B-NP
therapeutic  	therapeutic  	 JJ	I-NP
modalities  	modalities  	 NN	I-NP
can  	can  	 MD	O
be  	be  	 VB	O
supported  	supported  	 VBN	O
by  	by  	 IN	O
adjuvant  	adjuvant  	 JJ	B-NP
administration  	administration  	 NN	I-NP
of  	of  	 IN	O
genetically  	genetically  	 RB	O
modified  	modified  	 VBN	B-NP
vaccines 	vaccines 	 NNS	I-NP
,  	,  	 ,	O
as  	as  	 RB	O
well  	well  	 RB	O
as  	as  	 RB	O
by  	by  	 IN	O
depletion  	depletion  	 NN	O
of  	of  	 IN	O
immunosuppressive  	immunosuppressive  	 JJ	B-NP
immunocyte  	immunocyte  	 JJ	I-NP
subsets 	subsets 	 NN	I-NP
.  	.  	 .	O
The  	The  	 DT	O
purpose  	purpose  	 NN	O
of  	of  	 IN	O
this  	this  	 DT	O
review  	review  	 NN	O
was  	was  	 VBD	O
to  	to  	 TO	O
summarize  	summarize  	 VB	O
and  	and  	 CC	O
evaluate  	evaluate  	 VB	O
the  	the  	 DT	O
results  	results  	 NNS	O
obtained  	obtained  	 VBN	O
with  	with  	 IN	O
the  	the  	 DT	O
administration  	administration  	 NN	B-NP
of  	of  	 IN	O
genetically  	genetically  	 RB	O
modified  	modified  	 VBN	O
cellular  	cellular  	 JJ	B-NP
vaccines  	vaccines  	 NNS	I-NP
as  	as  	 IN	O
well  	well  	 RB	O
as  	as  	 RB	O
with  	with  	 IN	O
depletion  	depletion  	 NN	O
of  	of  	 IN	O
immunosuppressive  	immunosuppressive  	 NNS	B-NP
immunocytes  	immunocytes  	 VBP	O
performed  	performed  	 VBN	O
as  	as  	 IN	O
treatment  	treatment  	 NN	O
of  	of  	 IN	O
minimal  	minimal  	 JJ	O
residual  	residual  	 JJ	B-NP
disease  	disease  	 NN	I-NP
after  	after  	 IN	O
surgery  	surgery  	 NN	O
/  	/  	 CD	O
chemotherapy  	chemotherapy  	 NN	O
in  	in  	 IN	O
the  	the  	 DT	O
experimental  	experimental  	 JJ	B-NP
model  	model  	 NN	I-NP
of  	of  	 IN	I-NP
murine  	murine  	 FW	I-NP
tumors  	tumors  	 FW	I-NP
mimicking  	mimicking  	 FW	I-NP
human  	human  	 FW	I-NP
HPV16-associated  	HPV16-associated  	 FW	I-NP
neoplasms 	neoplasms 	 FW	I-NP
.  	.  	 .	O
The  	The  	 DT	O
prospects  	prospects  	 NNS	O
and  	and  	 CC	O
limitations  	limitations  	 NNS	O
of  	of  	 IN	O
these  	these  	 DT	O
adjuvant  	adjuvant  	 JJ	B-NP
immunotherapeutic  	immunotherapeutic  	 JJ	I-NP
modalities  	modalities  	 NNS	I-NP
are  	are  	 VBP	O
discussed 	discussed 	 VBN	O
.  	.  	 .	O
